Humacyte, Inc. (NASDAQ:HUMA) Given Average Rating of "Buy" by Brokerages

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been assigned a consensus rating of "Buy" from the eight ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $11.71.

Several equities analysts have commented on HUMA shares. D. Boral Capital reiterated a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research note on Wednesday. HC Wainwright started coverage on shares of Humacyte in a research note on Wednesday, May 14th. They issued a "buy" rating and a $4.00 price target on the stock. Benchmark dropped their price target on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Finally, Wall Street Zen upgraded shares of Humacyte from a "sell" rating to a "hold" rating in a research note on Friday, June 27th.

Insider Activity

In related news, CFO Dale A. Sander purchased 20,000 shares of the company's stock in a transaction that occurred on Thursday, April 10th. The shares were purchased at an average price of $1.53 per share, for a total transaction of $30,600.00. Following the transaction, the chief financial officer directly owned 40,600 shares of the company's stock, valued at approximately $62,118. The trade was a 97.09% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders bought a total of 33,993 shares of company stock worth $52,224 over the last 90 days. Company insiders own 5.10% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Humacyte by 10.8% during the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock worth $28,294,000 after purchasing an additional 543,995 shares during the period. Northern Trust Corp lifted its holdings in shares of Humacyte by 11.5% during the fourth quarter. Northern Trust Corp now owns 901,194 shares of the company's stock worth $4,551,000 after purchasing an additional 92,708 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Humacyte during the fourth quarter worth $99,000. Swiss National Bank lifted its holdings in shares of Humacyte by 5.8% during the fourth quarter. Swiss National Bank now owns 172,100 shares of the company's stock worth $869,000 after purchasing an additional 9,400 shares during the period. Finally, CenterBook Partners LP acquired a new stake in shares of Humacyte during the fourth quarter worth $6,463,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Stock Down 1.2%

Shares of HUMA stock traded down $0.03 during trading hours on Monday, reaching $2.54. 5,488,006 shares of the stock were exchanged, compared to its average volume of 3,833,512. The business's fifty day moving average is $2.17 and its two-hundred day moving average is $2.92. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.68 and a quick ratio of 3.28. Humacyte has a 12-month low of $1.15 and a 12-month high of $9.79. The firm has a market capitalization of $394.00 million, a P/E ratio of -3.68 and a beta of 1.89.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.09. The firm had revenue of $0.52 million for the quarter, compared to analysts' expectations of $0.46 million. As a group, research analysts expect that Humacyte will post -1.27 EPS for the current fiscal year.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.